Sac TMT Improves Survival in Treated Endometrial Cancer

Company Merck; Kelun-Biotech Event Type Phase 3 results and publication Modality TROP2-directed antibody-drug conjugate Asset Sacituzumab tirumotecan (sac-TMT) Target TROP2 (topoisomerase-I payload) Disease Area Advanced or recurrent endometrial cancer Summary The global Phase III TroFuse-005 study presented and published online on 26 October found both…